<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247971</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104326</org_study_id>
    <nct_id>NCT04247971</nct_id>
  </id_info>
  <brief_title>Pulmonary Inflammation and Microbiome Changes With Bariatric Surgery in Obese Asthma</brief_title>
  <official_title>Pulmonary Inflammation and Microbiome Changes With Bariatric Surgery in Obese Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gain understanding of mechanisms whereby bariatric surgery&#xD;
      modulates pulmonary inflammation and pulmonary microbiome composition and how these changes&#xD;
      direct the pathobiology of human obese asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in leptin levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in adiponectin levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-8 levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-6 levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cystatin-c levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-17 levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-1beta levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TNF-α levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in YKL-40 levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by forced expiratory volume</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by forced vital capacity</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by fractional concentration of exhaled nitro oxide</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by FEV1/FVC</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by forced expiratory flow</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Asthma</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese, early-onset asthmatics</arm_group_label>
    <description>Obese adults (BMI&gt;or= 30) between the ages of 21-60 with an initial asthma diagnosis at &lt;12 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, late-onset asthmatics</arm_group_label>
    <description>Obese adults (BMI &gt; or = 30) between the ages of 21-60 with an initial asthma diagnosis at &gt;12 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese non-asthmatics</arm_group_label>
    <description>Obese adults (BMI &gt; or = 30) between the ages of 21-60 with no asthma diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>23 ml of blood collected</description>
    <arm_group_label>Obese non-asthmatics</arm_group_label>
    <arm_group_label>Obese, early-onset asthmatics</arm_group_label>
    <arm_group_label>Obese, late-onset asthmatics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sputum collection</intervention_name>
    <description>Induced sputum sample collected</description>
    <arm_group_label>Obese non-asthmatics</arm_group_label>
    <arm_group_label>Obese, early-onset asthmatics</arm_group_label>
    <arm_group_label>Obese, late-onset asthmatics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary function test</intervention_name>
    <description>Pulmonary function testing</description>
    <arm_group_label>Obese non-asthmatics</arm_group_label>
    <arm_group_label>Obese, early-onset asthmatics</arm_group_label>
    <arm_group_label>Obese, late-onset asthmatics</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and sputum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of 15-20 obese, early-onset asthmatic, 15-20 obese, late-onset asthmatic, and 15-20&#xD;
        obese non-asthmatic subjects will be recruited. Subjects in each group will undergo an&#xD;
        initial screening visit (V0) to establish the subject groups according to asthma diagnosis,&#xD;
        asthma onset age and type of scheduled surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Asthma Subjects&#xD;
&#xD;
          -  Outpatient adults of either sex 21-60 years of age with an initial asthma diagnosis at&#xD;
             &lt; 12 years of age (early-onset) or &gt;12 years of age (late-onset), as defined by the&#xD;
             NHLBI NAEPP guidelines (17).&#xD;
&#xD;
          -  Subjects with obesity (BMI ≥ 30 kg/m2).&#xD;
&#xD;
          -  Physician diagnosis of asthma.&#xD;
&#xD;
          -  Eligible and scheduled for bariatric surgery (Roux-en-Y gastric bypass, sleeve&#xD;
             gastrectomy or duodenal switch) and receiving care within the Duke Health System.&#xD;
&#xD;
        FEV1 within acceptable limits (&gt;45% predicted before and &gt;55% predicted after,&#xD;
        bronchodilator administration).&#xD;
&#xD;
          -  Relatively healthy subjects able to undergo sputum induction without complications.&#xD;
&#xD;
          -  Willing and able to give informed consent and adhere to visit/protocol schedules.&#xD;
&#xD;
          -  Read and write in English.&#xD;
&#xD;
        Non-Asthma Control Subjects&#xD;
&#xD;
          -  Outpatient adults of either sex 21-60 years of age.&#xD;
&#xD;
          -  Subjects with obesity (BMI ≥ 30).&#xD;
&#xD;
          -  Eligible and scheduled for bariatric surgery (Roux-en-Y gastric bypass, sleeve&#xD;
             gastrectomy or duodenal switch) at Duke Regional Hospital and receiving care at the&#xD;
             Duke Metabolic and -Weight Loss Surgery Center.&#xD;
&#xD;
          -  Normal lung function.&#xD;
&#xD;
          -  No clinical history of atopy.&#xD;
&#xD;
          -  No significant medical or psychological issues.&#xD;
&#xD;
          -  Healthy subjects able to undergo sputum induction without complications.&#xD;
&#xD;
          -  Willing and able to give informed consent and adhere to visit/protocol schedules.&#xD;
&#xD;
          -  Read and write in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children &lt; 21 years of age.&#xD;
&#xD;
          -  Inpatient status.&#xD;
&#xD;
          -  Ineligibility or not scheduled for bariatric surgery at the Duke Metabolic and Weight&#xD;
             Loss Surgery Center.&#xD;
&#xD;
          -  FEV1 is less than 45% predicted before, or less than 55% predicted after,&#xD;
             bronchodilator administration.&#xD;
&#xD;
          -  Upper or lower respiratory tract infection within one month of the study.&#xD;
&#xD;
          -  Use of systemic corticosteroids within four weeks of study.&#xD;
&#xD;
          -  Smoking (tobacco, e-cigarette, vaping or inhaled drugs) history &gt; 5 pack years or&#xD;
             smoking or vaping within the previous six months.&#xD;
&#xD;
          -  Significant non-asthma pulmonary disease (stable obstructive sleep apnea is not&#xD;
             excluded).&#xD;
&#xD;
          -  An ED visit or inpatient admission for a primary respiratory diagnosis within 60 days&#xD;
             of enrollment.&#xD;
&#xD;
          -  Poorly controlled concomitant conditions that pose additional procedure risk as&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  All patients on anticoagulants.&#xD;
&#xD;
          -  Uncontrolled sleep apnea.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Guerron Cruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen R. Burkett, BSHS</last_name>
    <phone>919-681-1878</phone>
    <email>ellen.burkett@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delinda Phillips</last_name>
    <phone>919-684-8631</phone>
    <email>delinda.phillips@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen R Burkett, BSHS</last_name>
      <phone>919-681-1878</phone>
      <email>ellen.burkett@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

